# Antibodies to Digoxin for Bipolar Disorder

> **NCT00550576** · PHASE2 · COMPLETED · sponsor: **Rambam Health Care Campus** · enrollment: 18 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Digibind (Fab)

## Key facts

- **NCT ID:** NCT00550576
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550576, "Antibodies to Digoxin for Bipolar Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00550576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*